Corrigendum to 'The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer' [European Journal of Cancer 154 (2021) 175-189].
- DOI
- 10.1016/j.ejca.2021.09.020
- Published
- 2021 Nov
- Container
- European journal of cancer (Oxford, England : 1990)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2021.09.020,
title = {Corrigendum to 'The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer' [European Journal of Cancer 154 (2021) 175-189].},
author = {Le Du F and Dièras V and Curigliano G},
year = {2021},
journal = {European journal of cancer (Oxford, England : 1990)},
doi = {10.1016/j.ejca.2021.09.020},
url = {https://doi.org/10.1016/j.ejca.2021.09.020}
}RIS
TY - JOUR TI - Corrigendum to 'The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer' [European Journal of Cancer 154 (2021) 175-189]. AU - Le Du F AU - Dièras V AU - Curigliano G PY - 2021 JO - European journal of cancer (Oxford, England : 1990) DO - 10.1016/j.ejca.2021.09.020 UR - https://doi.org/10.1016/j.ejca.2021.09.020 ER -
APA
F, L. D., V, D., & G, C. (2021). Corrigendum to 'The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer' [European Journal of Cancer 154 (2021) 175-189].. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2021.09.020
Source records
- pubmed · retrieved 2026-09-26T14:44:53.901Z